

**Table SI. Demographic and clinical characteristics of the participants at baseline**

Category	Children, <i>n</i> = 85			Adults, <i>n</i> = 139		
	Placebo, <i>n</i> = 43,	Active, <i>n</i> = 42	<i>p</i> -value*	Placebo, <i>n</i> = 71	Active, <i>n</i> = 68	<i>p</i> -value*
Age, years, mean (SD)	2.3 (1.3)	2.4 (1.3)	0.836	39.3 (14.6)	40.3 (16.6)	0.828
Range	0.3–5.2			17.4–75.6		
Sex, <i>n</i> (%)						
Male	20 (46.5)	21 (50.0)		28 (39.4)	18 (26.5)	
Female	23 (53.5)	21 (50.0)		43 (60.6)	50 (73.5)	
Race: White/Caucasian, <i>n</i> (%)	43 (100)	42 (100)		71 (100)	68 (100)	
Patients included in each 30-days period, <i>n</i>						
Days 0–30	43	42		71	68	
Days 30–60	33	35		65	64	
SCORAD at D10, mean (SD)	33.72 (13.08)	35.93 (14.66)	0.436	39.12 (14.46)	40.03 (13.56)	0.749
SCORAD at D0, mean (SD)	5.35 (5.04)	5.81 (5.88)	0.769	13.3 (7.0)	13.7 (6.6)	0.503
SCORAD range at D0	0–20			0–32.7		
DLQI, mean (SD)	–	–		7.78 (6.06)	7.79 (7.07)	0.743
IDQOL, mean (SD)	3.00 (3.11)	4.29 (4.40)	0.301	–	–	
DFI, mean (SD)	3.40 (4.28)	4.02 (5.15)	0.477	–	–	

\*Statistical significance between active and placebo arms was evaluated using a Mann & Whitney test.

DFI: Dermatitis Family Impact; DLQI: Dermatology Life Quality Index; IDQOL: Infant's Dermatitis Quality of Life index; SCORAD: SCORing Atopic Dermatitis; SD: standard deviation.